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Abstract
Background: Cyclooxygenase-2 (COX-2) and the bombesin (BBS)-like peptide, gastrin-releasing peptide (GRP), have
been implicated in the progression of hormone-refractory prostate cancer; however, a mechanistic link between
the bioactive peptide and COX-2 expression in prostate cells has not been made.
Results: We report that BBS stimulates COX-2 mRNA and protein expression, and the release of prostaglandin E2
from the GRP receptor (GRPR)-positive, androgen-insensitive prostate cancer cell line, PC-3. BBS-stimulated COX-2
expression is mediated, in part, by p38
MAPK and PI3 kinase (PI3K)/Akt pathways, and blocked by a GRPR antagonist.
The PI3K/Akt pathway couples GRPR to the transcription factor, activator protein-1 (AP-1), and enhanced COX-2
promoter activity. Although BBS stimulates nuclear factor-kappaB (NF-B) in PC-3, NF-B does not regulate
GRPR-mediated COX-2 expression. The p38
MAPK pathway increases BBS-stimulated COX-2 expression by slowing the
degradation of COX-2 mRNA. Expression of recombinant GRPR in the androgen-sensitive cell line LNCaP is
sufficient to confer BBS-stimulated COX-2 expression via the p38
MAPK and PI3K/Akt pathways.
Conclusions: Our study establishes a mechanistic link between GRPR activation and enhanced COX-2 expression in
prostate cancer cell lines, and suggests that inhibiting GRPR may, in the future, provide an effective therapeutic
alternative to non-steroidal anti-inflammatory drugs for inhibiting COX-2 in patients with recurrent prostate cancer.
Keywords: gastrin-releasing peptide receptor, signal transduction, prostate cancer, neuroendocrine differentiation,
hormone-refractory
Background
Prostate cancer is the most commonly diagnosed form
of cancer among men in the United States and second
only to lung cancer as a cause of cancer-related death.
In 2010, the American Cancer Society estimates that
over 217,000 new cases of prostate cancer will be diag-
nosed and more than 32,000 men will die, most from
metastatic, androgen (hormone)-refractory disease
(American Cancer Society. Cancer Facts &Figures 2010,
Atlanta: American Cancer Society; 2010; http://www.
cancer.org).
Hormone-refractory prostate cancer is characterized, in
part, by focal expansion of a malignant cell subpopulation
with neuroendocrine (NE) features. NE cells lack expres-
sion of androgen receptors, express NE markers, such as
neuron-specific enolase and chromogranin A, and con-
tain numerous secretory granules rich in neuropeptides
including calcitonin, calcitonin gene-related peptide [1],
parathyroid hormone-related protein [2], and the bombe-
sin (BBS)-like peptide, gastrin-releasing peptide (GRP).
Although the impact of NE differentiation on poor prog-
nosis and androgen independence has been extensively
studied [3], the molecular mechanisms linking NE tumor
cells and their bioactive neuropeptides to disease pro-
gression are still unclear.
Increased expression of cyclooxygenase-2 (COX-2), an
enzyme that catalyzes the synthesis of prostanoids such
as prostaglandin E2 (PGE2)f r o ma r a c h i d o n i ca c i d[ 4 - 6 ] ,
was identified as an independent predictor of prostate
cancer progression [7]. Clinical trials using COX-2
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prostate cancer have suggested that COX-2 inhibition
may improve survival [8,9], and pre-clinical studies with
cell lines and animal models have established a func-
tional link between COX-2 expression and an aggressive
cancer phenotype. Specifically, Dandekar and coworkers
[10] have demonstrated that overexpression of COX-2
in human prostate cancer cell lines induced chemother-
apeutic resistance, decreased apoptosis, and increased
tumor angiogenesis and growth. In a transgenic mouse
model of prostate carcinogenesis, pharmacological inhi-
bitors of COX-2 suppressed tumor growth and
decreased metastatic spread [11,12]. Together, these stu-
dies implicate COX-2 in prostate cancer progression;
however, the molecular mechanisms leading to its
increased expression and the relationship between
enhanced expression and NE differentiation requires
further investigation.
COX-2 expression can be induced by multiple factors
including growth factors, proinflammatory cytokines,
and peptide hormones [13-15]. BBS is a 14-amino acid
peptide originally isolated from the skin of the frog,
Bombina bombina, and is a functional homologue to
GRP. In humans, GRP binds with high affinity to the
GRP receptor (GRPR), a member of the G protein-
coupled receptor superfamily [16]. Clinical, histological,
and experimental observations have implicated GRP and
GRPR in the pathophysiology of prostate cancer pro-
gression. Logothetis and Hoosein [17] reported that 40%
of patients with hormone-refractory prostate cancer had
significantly elevated levels of GRP in their serum. GRP
and GRPR are expressed by NE cells in prostate cancer
tissue and by prostate cancer-derived cell lines [18,19];
BBS stimulates the growth of both orthotopic and ecto-
pic prostate cancer cell xenografts in athymic nude mice
through GRPR-mediated mechanisms [20,21]. BBS also
promotes expression of metalloproteinases [22] and
increases prostate cancer cell migration and invasion
[23-25]. Previously, we reported that BBS stimulates the
expression of the proangiogenic genes IL-8 and vascular
endothelial growth factor (VEGF) in humanp r o s t a t e
cancer cell lines [26].
Since COX-2 and GRPR both regulate cellular pro-
cesses that contribute to the progression and metastatic
spread of prostate cancers and, because BBS has been
shown to regulate COX-2 expression in cells from other
tissues [27-29], we reasoned that GRPR activation and
C O X - 2e x p r e s s i o nm a yb em e c h a n i s t i c a l l yl i n k e di n
prostate cancer cells. Here, we report that BBS stimu-
lates an increase in COX-2 mRNA, protein expression,
and the release of PGE2 from the GRPR-positive, andro-
gen-insensitive prostate cancer cell line, PC-3. The sti-
mulatory effects of BBS on COX-2 expression and PGE2
production are mediated by p38
MAPK and PI3 kinase
(PI3K)/Akt pathways and blocked by the selective GRPR
antagonist BIM26226. The PI3K/Akt pathway couples
GRPR to the activation of the transcription factor, acti-
vator protein-1 (AP-1), and enhances COX-2 promoter
activity. BBS also stimulates nuclear factor-kappaB (NF-
B) activation in PC-3; however, NF-B does not regu-
late GRPR-mediated COX-2 expression. The p38
MAPK
pathway increases BBS-stimulated COX-2 expression by
slowing the degradation of COX-2 mRNA. Expression
of recombinant GRPR in the GRPR-negative, androgen-
sensitive cell line LNCaP, is sufficient to confer BBS-sti-
mulated COX-2 expression via the p38
MAPK and PI3K/
Akt pathways. Together, these results define a molecular
mechanism for enhanced COX-2 expression in prostate
cancer cells, and suggest a means by which NE-differen-
tiated tumor cells and their bioactive neuropeptides may
contribute to disease progression.
Results
BBS stimulates COX-2 mRNA and protein expression
To determine whether BBS stimulates COX-2 expres-
sion, we treated the androgen-insensitive prostate cancer
cell line PC-3 with BBS and measured steady-state levels
of COX-2 mRNA and protein at various time points.
Compared to vehicle-treated [phosphate buffered saline
(PBS)] control cultures, COX-2 mRNA was increased at
1 h following addition of BBS (10 nM) and peaked
b e t w e e n2a n d6h( F i g u r e1 A ) .I n c r e a s e dC O X - 2p r o -
tein was also detected at 1 h following BBS treatment,
peaked between 4 and 8 h, and returned to baseline
levels by 24 h (Figure 1B). Consistent with the lack of
change in basal COX-2 mRNA levels over the time
course (Figure 1A); we did not observe a change in the
basal expression of COX-2 protein in non-treated cells
(data not shown). Induction of both COX-2 mRNA and
protein expression was dependent on the concentration
of BBS. Increased COX-2 mRNA and protein levels
were detected in cells treated with as little as 0.1 nM
BBS for 4 h and maximal induction was observed in
cells treated with 1 to 10 nM BBS (Figure 1C and 1D,
respectively).
GRPR mediates BBS-stimulated COX-2 protein expression
and PGE2 synthesis
COX-2 converts arachidonic acid, released from phos-
pholipids by the action of phospholipase A2,t op r o s t a -
glandin H2 - the common precursor of all prostaglandins,
including PGE2. To assess whether BBS stimulation of
COX-2 expression was associated with an increased pros-
taglandin synthesis, the levels of PGE2 released from
PC-3 cells were measured using an enzyme-linked immu-
nosorbent assay. Compared to vehicle-treated control
cultures, BBS induced a time-dependent increase in the
PGE2 levels that peaked between 4 and 16 h (Figure 2A,
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GRPR-selective antagonist, BIM26226 ([D-F5-Phe
6,
D-Ala
11]Bombesin(6-13)Ome] [30], (1 μM) for 30 min
blocked the BBS-induced increase in PGE2 (Figure 2A,
black bar vs. cross-hatched bar), *p ≤ 0.01). Consistent
with this observation, BIM26226 also inhibited BBS-
stimulated increases in COX-2 protein expression
(Figure 2B).
BBS activates multiple intracellular signaling pathways in
PC-3 cells
COX-2 expression is regulated by multiple intracellular
signaling pathways including the MAPK pathways,
MEK/ERK and p38
MAPK, and the PI3K/Akt pathway
[31]. To determine if these pathways were activated by
BBS, PC-3 cells were treated with peptides over a time
course and the activation state of each pathway assessed
by immunoblotting. BBS treatment (10 nM) induced a
time-dependent increase in the levels of activated (phos-
phorylated) ERK1 (pERK1) and ERK2 (pERK2) (Figure
3A). The levels increased rapidly with a peak phosphor-
ylation occurring between 1 and 15 min and remained
elevated above baseline 60 min after treatment with BBS
(Figure 3A). BBS stimulated a transient activation of
p38
MAPK. The levels of phospho-p38
MAPK (pp38
MAPK)
peaked between 5 and 30 min and, in contrast to the
activation of either ERK1 and 2 or Akt, returned to
baseline levels by 60 min (Figure 3A). The levels of
phospho-Akt (pAkt) increased at 5 min, reached a pla-
teau by 15 min, and remained elevated for the duration
o ft h et i m ec o u r s e( F i g u r e3 A ) .O v e rt h es a m et i m e
course, we did not observe any change in the activation
state of these pathways in non-stimulated cells (data not
shown).
Figure 1 BBS treatment induces a time- and dose-dependent increase in COX-2 mRNA and protein expression. A) Autoradiography of
Northern blots demonstrating time-dependent increase in COX-2 mRNA steady-state levels in PC-3 cells treated with 10 nM of BBS. Blots were
reprobed for 18S ribosomal RNA to ensure equivalent loading and transfer of total RNA in each lane. B) Immunoblot showing time-dependent
increase in COX-2 protein levels following treatment with BBS (10 nM). Blots were reprobed for b-actin to ensure the equivalent loading and
transfer of protein samples. C, D) Effects of a 4-h treatment with different concentrations of BBS on COX-2 mRNA (C) and protein (D) expression.
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p38
MAPK and PI3K/Akt pathways, but not the MEK/ERK
signaling axis
To assess the roles of the p38
MAPK,P I 3 K / A K t ,a n d
MEK/ERK pathways in BBS-stimulated COX-2 expres-
sion, PC-3 cells were pretreated (30 min) with either the
p38
MAPK inhibitor (SB203580, 10 μM), the PI3K inhibi-
tor (LY294002, 25 μM) or the MEK1,2 inhibitor
(PD98059, 20 μM) and then stimulated with BBS (10
nM) for 4 h. Agonist treatment failed to increase either
COX-2 mRNA or protein levels when the cells were
pretreated with either SB203580 or LY294002 (Figure
3B and 3C). In contrast, pretreatment with PD98059 did
not inhibit BBS-stimulated increases in COX-2 mRNA
nor protein expression. Consistent with these observa-
tions, SB203580 or LY294002 inhibited BBS-stimulated
PGE2 release from PC-3 cells, whereas PD98059 had no
effect (Figure 3D).
Inhibition of PI3K/Akt pathway reduces BBS-stimulated
COX-2 promoter activity
The cellular levels of COX-2 mRNA can be regulated
both by enhanced gene transcription and inhibition of
message degradation [31,32]. To determine whether BBS
treatment enhanced COX-2 gene transcription, PC-3
cells were first transiently transfected with a transcrip-
tion reporter construct consisting of 1.4 kb of the
human COX-2 promoter coupled to a luciferase gene
and then stimulated with BBS over a time course. BBS
induced a time-dependent increase (1.4- to 2.3-fold) in
COX-2 promoter activity when compared to vehicle-
treated control cell cultures (Figure 4A). To determine
whether the p38
MAPK or PI3K/Akt pathways were
involved in BBS-stimulated COX-2 transcription, cells
were pretreated with SB203580 (10 μM) or LY294002
(25 μM) for 30 min followed by a 6-h treatment with
BBS (10 nM). Compared to BBS treatment alone,
LY294002 inhibited approximately 50% of the increase
in BBS-stimulated luciferase activity (Figure 4B). In con-
trast, SB203580 had no effect on BBS-stimulated COX-2
promoter activity (Figure 4B), suggesting that the PI3K/
Akt pathway, not the p38
MAPK pathway, is involved in
BBS-induced COX-2 gene transcription in PC-3 cells.
LY294002 inhibits BBS-stimulated AP-1 binding activity
but not NF-B nuclear translocation
The human COX-2 promoter contains multiple regula-
tory sites that bind transcription factors including
nuclear factor-B( N F - B) [33,34] and AP-1 [35]. Elec-
trophoresis mobility shift assays showed that BBS treat-
ment of PC-3 cells induced an increase in AP-1 binding
activity (Figure 4C) that was inhibited by pretreatment
with LY294002 (25 μM) for 30 min (Figure 4C), suggest-
ing that PI3K/Akt-mediated AP-1 activation is involved
in BBS regulation of the COX-2 promoter activity. In
addition to activation of AP-1, we previously reported
Figure 2 GRP receptor mediates BBS-stimulated PGE2 release and COX-2 expression. A) PC-3 cells were pre-treated with BIM26226 (1 μM)
for 30 min and then incubated with or without 10 nM of BBS over a time course. The amount of PGE2 released into the culture media was
assessed by enzyme-linked immunoassay (Methods). The data was normalized to total cellular protein per well. [† BBS vs. vehicle (no treatment),
p < 0.01; * BBS+BIM26226 vs. BBS alone, p < 0.01]. B) Immunoblot showing the effects of BIM26226 on BBS-stimulated COX-2 protein expression.
PC-3 cells were pretreated with BIM26226 for 30 min and then treated with BBS for 4 h. Blots were reprobed for b-actin to ensure the
equivalent loading and transfer of protein samples.
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[26]. NF-B is an inducible dimeric transcription factor
that belongs to the Rel/NF-Bf a m i l yo fp r o t e i n s[ 3 6 ] .
Activation of NF-B involves its dissociation from the
inhibitor protein, IB, followed by its translocation to
the nucleus where it binds to specific DNA sequences in
the promoter regions of multiple genes including COX-
2 [37]. To confirm that BBS activated NF-B, PC-3 cells
were treated with peptide for 30 min, fixed, and immu-
nostained with an antibody to the p65 subunit of NF-
B. Treated cells demonstrated increased nuclear NF-B
immunoreactivity when compared with vehicle-treated
cultures (Figure 4D). Pretreating cells with the NF-B
inhibitor, curcumin (diferuloylmethane, 20 μM), inhib-
ited both BBS- and TNF-a-induced NF-B translocation
to the nucleus (Figure 4D). To assess the role of the
PI3K/Akt pathway in BBS-induced NF-B activation,
cells were pretreated with LY294002 for 30 min, fol-
lowed by 30 min treatment with agonist. LY294002 had
no effect on the BBS-induced NF-B translocation
(Figure 4D). Since LY294002 inhibits COX-2 mRNA
expression (Figure 3A), COX-2 promoter activity (Figure
4B) and AP-1 binding (Figure 4C), these data suggest
that AP-1 and not NF-B regulates BBS-stimulated
COX-2 promoter, in part, through activation of the
PI3K/Akt pathway.
p38
MAPK activity enhances the stability of COX-2 mRNA
Since inhibition of the p38
MAPK pathway did not block
BBS-stimulated COX-2 promoter activity (Figure 4B),
we assessed its potential role in regulating COX-2
mRNA stability. PC-3 cells were stimulated for 4 h with
BBS (10 μM) and then treated with actinomycin D (5
μM) alone or in combination with either SB203580 or
LY294002. RNA was isolated from the cells over a time
course and the level of COX-2 mRNA at each time
point assessed by Northern blotting (Figure 5A). COX-2
mRNA degraded slowly in BBS-stimulated cells treated
with actinomycin D alone or in combination with
LY294002; less than 20% of the COX-2 message was
Figure 3 The PI3K/Akt and p38
MAPK pathways mediate BBS-stimulated COX-2 expression and PGE2 synthesis. A) PC-3 cells were treated
with 10 nM BBS over a time course, and the levels of phosphorylation (activated) of ERK1 and ERK2 (pERK1 and pERK2), p38
MAPK (pp38
MAPK) and
Akt (pAkt) were detected by immunoblotting with phospho-specific antibodies. The level of total Akt was assessed to insure the equivalent
loading of protein samples in each lane. B, C) Effects of the p38
MAPK inhibitor SB203580, the PI3K/Akt inhibitor, LY294002, and the ERK inhibitor,
PD98059 on BBS-stimulated COX-2 mRNA (B) and protein (C) expression. Blots were reprobed for 18S ribosomal or b-actin to ensure the
equivalent loading and transfer of RNA and protein samples, respectively. D) Effects of the SB203580, LY294002, PD98059 on BBS-stimulated (6 h)
PGE2 elaboration from PC-3 cells [† BBS vs. vehicle, p ≤ 0.01; * BBS+SB203580 or LY294002 vs. BBS alone, p ≤ 0.01, n = 3].
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with plasmids containing the 1.4 kb human COX-2 promoter 5’ of a luciferase reporter gene and b-galactosidase. A) Twenty-four hours after
transfection, cells were treated either with vehicle or 10 nM BBS for 2, 4, and 6 h. Changes in luciferase activity (mean ± S.D, n = 3) are
expressed relative to vehicle treated at each time point after normalizing for transfection efficiency using b-galactosidase activity [* BBS vs. time-
point matched vehicle control, p < 0.05]. B) Pre-treatment with LY294002 (25 μM) partially inhibited BBS-stimulated COX-2 promoter activity [*
LY294002 vs. BBS alone, p < 0.05, n = 3], whereas SB203580 (10 μM) had no effect. C) Autoradiogram showing binding of nuclear proteins to
32P-labeled oligonucleotide containing the AP-1 consensus sequence [lane 1, radiolabeled probe only; lane 2, nuclear proteins + radio-labeled
probe and excess unlabeled probe; lane 3, nuclear protein from vehicle-treated cells; lane 4 nuclear proteins from cells treated with BBS (10 nM)
for 30 min; lanes 5 and 6, nuclear proteins from cells pretreated with LY294002 (25 μM) for 30 min followed by vehicle or BBS for 30 min]. D)
PC-3 cells were treated with BBS (10 nM) or TNF-a (10 ng/ml) alone or in combination with inhibitors for 30 min, fixed, and immunostained
with an antibody to the p65 subunit of NF-B. Quantification of the effects of curcumin (Cur) (20 μM) and LY294002 (LY) (25 μM) on BBS-
stimulated NF-B nuclear translocation. Data are expressed as the ratio of NF-B-positive stained nuclei divided by the total number of cells per
high power field (200X). Four fields were counted for each condition from 3 independent experiment [† BBS or BBS + LY294002 vs. vehicle or
LY294002 alone, p ≤ 0.001; * BBS + curcumin vs. BBS alone or TNFa + curcumin vs. TNFa alone, p ≤ 0.001].
Figure 5 p38
MAPK activity enhances COX-2 mRNA stability. A) Autoradiogram of Northern blot showing the effects of p38
MAPK and PI3K/Akt
inhibition on COX-2 mRNA degradation. Cells were stimulated with BBS for 4 h, and attenuated 4 μM actinomycin D was added (t = 0) alone or
with SB203580 or LY294002 and total RNA isolated at 15, 30, 60, and 90 min. Blots were reprobed for 18S ribosomal RNA to ensure equivalent
loading and transfer of total RNA in each lane. B) Graph of densitometric analysis of blot in panel A.
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contrast, the levels of COX-2 mRNA decreased rapidly
in cells treated with a combination of actinomycin D
and SB203580; approximately 50% of the COX-2 mes-
sage was degraded in cells treated for 30 min (Figure
5B), suggesting that p38
MAPK activity stabilizes BBS-
induced increases in COX-2 mRNA levels.
Expression of GRPR is sufficient to confer BBS-inducible
COX-2 expression in LNCaP cells
LNCaP prostate cancer cells, in contrast to the PC-3
cells, are androgen-responsive, poorly invasive [23] and
do not have specific GRPR binding sites, as assessed by
radioligand binding to
125I[Tyr4]-Bombesin [38] and
[Ca
2+]i mobilization in response to BBS [39]. To deter-
mine whether the acquisition of the GRPR was sufficient
to confer BBS-inducible COX-2 expression, LNCaP cells
were stably transfected with an expression plasmid con-
taining GRPR cDNA downstream of the constitutively-
active CMV promoter [40]. GRPR mRNA expression
was confirmed by Northern blot (Figure 6A), and the
functional status of the receptor was demonstrated by
intracellular Ca
2+ imaging using Fura-2 (Figure 6B).
Immunoblots revealed that BBS stimulated COX-2 pro-
tein expression in GRPR-transfected cells, but had no
effect on LNCaP cells expressing control vector (Figure
6C). Also, similar to PC-3 cells, pretreatment of GRPR-
transfected LNCaP cells with either SB203580 (10 μM)
or LY294002 (25 μM) completely inhibited BBS-stimu-
lated PGE2 release, suggesting that GRPR regulates
COX-2 activity via the p38
MAPK and PI3K/Akt pathways
(Figure 6D).
Discussion
Although the aberrant overexpression of COX-2, the
BBS-like peptide, GRP, and GRPR has been documented
for prostate cancers with NE features, particularly in the
setting of recurrent disease [3,7,41], a mechanistic link
between GRPR activation and COX-2 expression in
prostate cancer cells has not been made. The studies
presented here establish that BBS can stimulate COX-2
expression and begins to define the molecular signal
transduction pathways linking GRPR to COX-2.
Expression of COX-2 can be regulated by multiple sig-
naling pathways that affect both gene transcription and
post-transcriptional mRNA processing [42-45]. We
found that BBS-stimulated COX-2 expression requires
the activation of both the p38
MAPK a n dP I 3 K / A k tp a t h -
ways in PC-3 and LNCaP cells expressing recombinant
GRPR. LY294002 partially inhibited BBS-stimulated
COX-2 promoter activity, decreased COX-2 mRNA and
protein levels, and reduced PGE2 secretion, whereas,
inhibition of p38
MAPK destabilized BBS-stimulated
COX-2 mRNA, resulting in a decrease of both COX-2
p r o t e i ne x p r e s s i o na n dP G E 2 production. The MEK
inhibitor, PD98059, had no effect on either BBS-stimu-
lated COX-2 expression or PGE2 secretion, in contrast
to previously published data from our laboratory show-
ing that, in intestinal epithelial cells, BBS stimulated
COX-2 expression through a MEK/ERK-dependent
pathway [40].
Sequence analysis of the 5’-flanking region of the
human COX-2 gene has identified multiple potential
transcriptional regulatory elements including two NF-B
sites located at 213 to 222 and 438 to 447 [46,47] base
pairs 5’ of the transcriptional start site, and an AP-1 site
located ~60 base pairs upstream from the start site [31].
Although we have previously reported NF-B-dependent
regulation of VEGF and IL-8 expression [26] in PC-3
cells, in the present study NF-B does not appear to be
involved in GRPR-regulation of the endogenous COX-2
promoter. This conclusion is based on the observation
that LY294002 can inhibit COX-2 mRNA expression
and partially reduced promoter activity, but does not
block BBS-stimulated NF-B activation. In contrast,
LY294002 does inhibit BBS-induced AP-1 binding, sug-
gesting that AP-1 may be the primary transcription fac-
tor involved in BBS-stimulated COX-2 mRNA
expression in PC-3 cells. These findings are consistent
with data from intestinal epithelial cells showing that
BBS-stimulated COX-2 expression via an AP-1-depen-
dent pathway [40].
Despite the fact that more than 80% of patients with
late stage prostate cancer initially respond to androgen-
ablation therapy [48], more than half will progress to a
hormone-refractory disease within 16 to 18 months
after treatment [49]. Elucidation the molecular mechan-
isms mediating the conversion of androgen-sensitive
prostate cancers to hormone-refractory disease is one of
the most critical tasks in improving current treatment
strategies and patient survival. A recent study evaluating
archival prostate cancer specimens by immunohisto-
chemical methods identified COX-2 levels as an inde-
pendent predictor of prostate cancer recurrence [7]. At
62-months follow-up, COX-2 immunostaining predicted
cancer progression with 82% sensitivity and 81% specifi-
city. Additionally, two clinical trials have generated
early, but promising, data that inhibition of COX-2 can
benefit patients with biochemical recurrence of prostate
cancer (i.e., the same transcription factor can regulate
increasing PSA levels, but no clinical evidence of disease
following androgen-ablation therapy). In the first study,
Pruthi and associates [8] studied 12 patients who were
given the selective COX-2 inhibitor, celecoxib, following
a diagnosis of biochemical recurrence. Five of the 12
patients had decreased PSA levels, and three of the 12
had stabilization of their PSA levels at 3, 6, and 12
months following the initiation of therapy. In a second
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40) to celecoxib (n = 38), the group receiving celecoxib
for 6 months showed a significantly decreased rate of
rise in PSA levels when compared to the placebo control
patients [9]. Together, these trials suggest that targeting
COX-2 can be beneficial. Unfortunately, the studies
were terminated by the United States Food and Drug
Administration because of the potential risk of cardio-
vascular complications with the current cadre of COX-2
inhibitors.
Novel strategies for inhibiting COX-2 could once
again make it a viable therapeutic target in the future.
Inhibiting GRPR may provide an effective therapeutic
alternative for decreasing COX-2 expression and activity
in patients with recurrent prostate cancer. Proof of this
concept is provided by a recent pre-clinical study that
evaluated the effects of the GRPR antagonist, RC-3940-
II, in an orthotopic non-small-cell lung carcinoma
model [29]. Similar to prostate cancers, lung cancers
express GRP and GRPR [50] where they promote tumor
progression and metastatic spread through autocrine
and paracrine mechanisms. Hohla and colleagues [29]
showed that daily treatment of NSCLC tumor-bearing
mice with RC-3940-II reduced the mean lung tumor
weight by up to 53%. Importantly, the decreased tumor
growth was associated with antagonist-induced
decreases in p-Akt levels and COX-2 expression sug-
gesting, together with the data presented herein, that
GRPR blockage may be an effective means of decreasing
COX-2 expression within receptor-positive tumor tissue.
Figure 6 Expression of GRPR in LNCaP cells confers BBS-stimulated COX-2 expression and PGE2 synthesis. A) Northern blot confirming
the expression of GRPR in transfected LNCaP cells (n = 1). B) Time-dependent change in intracellular Ca
2+ concentration measured with Fura-2;
comparison of GRPR transfected (LNCaP/GRPR) to control vector-transfected LNCaP cells (LNCaP/Vector) (tracing represents the average change
in [Ca
2+]i from 40 cells). C) Immunoblot showing effects of BBS treatment on COX-2 protein expression in LNCaP/Vector and LNCaP/GRPR cells.
PC-3 cells were used as a positive control. Blots were reprobed for b-actin to ensure the equivalent loading and transfer of protein samples. D)
Effects of SB203580 and LY294002 on BBS-stimulated PGE2 elaboration form LNCaP/GRPR cells. Cells were pretreated for 30 min with the
inhibitors and then stimulated with BBS for 6 h. PGE2 levels in the culture media were determined as described (Material and Methods) [† BBS
vs. vehicle, p < 0.01; * BBS+SB203580 or LY294002 vs. BBS alone, p < 0.01].
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Our study establishes a mechanistic link between GRPR
activation and enhanced COX-2 expression in prostate
cancer cell lines, and suggests that inhibiting GRPR may
provide an alternative to non-steroidal anti-inflamma-
tory drugs for inhibiting COX-2 in patients with recur-
rent prostate cancer.
Methods
Materials
BBS was purchased from Bachem (Torrance, CA). Inhi-
bitors of p38
MAPK (SB203580), MEK-1 and -2
(PD98059), and PI3-kinase (PI3K) (LY294002) were pur-
chased from CalBioChem (San Diego, CA). The anti-
body to phospho-p38
MAPK was purchased from
Promega (Madison, WI). Antibodies to ERK-1 and -2,
phospho-ERK1 and ERK2, p38
MAPK, and human COX-2
antibody were obtained from Santa Cruz (Santa Cruz,
CA). Antibodies to Akt and phosphor-Akt were pur-
chased from Cell Signaling Technology, Inc. (Beverly,
MA). The b-actin antibody was purchased from SIGMA
(St. Louis, MO). Arachidonic acid was purchased from
Cayman Chemical (Ann Arbor, MI). GRPR expression
vector was a gift from Dr. James F. Battey (National
Institutes of Health, Bethesda, MD).
Cell culture
The PC-3 and LNCaP cell lines were obtained from
American Type Culture Collection (Manassas, VA) and
cultured at 37°C in RPMI 1640 supplement with L-glu-
tamine, 10% heat-inactivated fetal bovine serum (FBS)
(Hyclone Laboratories Inc., Logan, UT) and 1 mM
sodium pyruvate (Sigma-Aldrich Corp., St. Louis, MO).
For all experiments, the cells were cultured in serum-
free media for 18-24 h prior to treatments.
RNA isolation and Northern blot analysis
Cells (1.5 × 10
6) were plated in 100 mm tissue culture
dishes. After 24 h, the cells were serum starved for an
additional 20 h and then treated as described in the figure
legends. RNA was isolated using ULTRASPEC™RNA Iso-
lation System (Biotecx, Houston, TX), resolved on 1%
agarose/formaldehyde gels, and transferred onto Hybond-
N+ membrane (Amersham Biosciences Corp, Piscataway,
NJ). The membrane was hybridized with human COX-2
cDNA probe labeled with [a-
32P]dATP (Perkin Elmer Life
Sciences Inc., Boston, MA) using a random-priming
DNA-labeling kit (Stratagene, Cedar Creek, TX). The spe-
cific hybridization was visualized by autoradiography. The
membrane was re-hybridized with a probe for 18S riboso-
mal RNA to confirm RNA integrity and equivalent loading
of each sample. With the exception of the Figure 6A, all
RNA isolations and Northern blots were repeated a mini-
mum of three times.
Western blot analysis
Cells were incubated in serum-free media for the indi-
cated period of time, treated with peptide hormone and/
or drug as described in the figure legends and lysed
using a solution containing 50 mM Tris (pH 7.4), 150
mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM
sodium orthovanadate, 5 mM b-glycerophosphate, 10
mM sodium pyrophosphate, 1 mM NaF, 1 mM PMSF,
and 1 Protease Inhibitor Cocktail Tablet/50 ml (Roche
Applied Science, Indianapolis, IN). The detergent-inso-
luble cellular material was removed by centrifugation at
14000 rpm for 15 min, and the protein concentration of
the supernatant was determined using BioRad Dye
Reagent Concentrate (BioRad Laboratories, Inc., Her-
cules, CA). Proteins (40-100 μg/lane) were resolved on
4-12% continuous gradient Bis-Tris-HCl buffered polya-
crylamide gels (Invitrogen, Carlsbad, CA), transferred to
a PVDF membrane (Millipore Corporation, Bedford,
MA), and blocked with 5% non-fat milk. Membranes
were probed with the primary antibodies at dilutions
indicated in the figure legends. Specific immunoreactive
bands were detected using enhanced chemiluminescence
(ECL)™ Western Blotting Detection Reagent (Amer-
sham Biosciences Corp, Piscataway, NJ) and Kodak X-
Omat film. All protein isolations and Western blots
were repeated a minimum of three times.
PGE2 assay
Cells (1.2 × 10
5/well) were seeded in 12-well plates for
24 h. After culturing for 20 h in serum-free media, the
cells were treated with BBS for the period of 4, 8, 10,
16, and 24 h. Arachidonic acid (15 μM) was added 30
min prior to the collection of media. Culture media
(100 μl) from each well were analyzed for PGE2 by
using Biotrak Enzyme immunoassay (EIA) system
(Amersham Biosciences, Piscataway, NJ). All assays
where repeat at least three times.
Luciferase reporter gene assay
Cells (1.2 × 10
5/well) were seeded into 12-well plates and
co-transfected with 250 ng of plasmid DNA containing
the human COX-2 promoter coupled to a luciferase repor-
ter gene and 30 ng of plasmid containing b-galactosidase
using LipofectAMINE™ Reagent (Invitrogen, Carlsbad,
CA). Cells were treated as described in the figure legends.
Luciferase and b-galactosidase activity were assayed using
Enhanced Luciferase Assay Kit (BD Biosciences, San
Diego, CA) and Galacto-Light Plus™ Systems (Applied
Biosystems, Bedford, MA), respectively. The transfections
and luciferase assays were repeated three times.
Immunofluorescence microscopy
PC-3 cells were cultured on glass coverslips. Before
immunostaining for NF-B p65 subunit, the cells were
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nM), TNF-a (10 ng/ml), or a combination of curcumin
and BBS or TNF-a for 30 min at 37°C, fixed with 4%
paraformaldehyde (15 min), permeabilized with 0.3%
Triton X-100 (10 min), and incubated in blocking solu-
tion (1% BSA in PBS; 20 min). After incubating the cells
with anti-NF-B antiserum (1:100 dilution; San Cruz
Biotechnology Inc., San Cruz, CA) for 1 h at room tem-
perature, the cells were washed three times with PBS
and incubated with a goat anti-rabbit IgG antibody
labeled with Alexa 488 (Molecular Probes, Inc., Eugene,
OR; 1:2000; 30 min). The immunostaining procedure
was repeated at least three times. Specific immunostain-
ing was visualized with a Nikon Eclipse fluorescence
microscope.
Electrophoretic mobility shift assay
Nuclear extracts were prepared as previously described
[26]. Oligonucleotides (Promega, Madison, WI) of which
the sequence corresponding to the AP-1 binding site
consensus sequence (5’- CGC TTG ATG AGT CAG
CCG GAA -3’) were end-labeled with [g-
32P]ATP and
T4 polynucleotide kinase respectively. Electrophoretic
mobility shift assay (EMSA) reaction mixtures contained
50,000 cpm of
32P-end-labeled oligonucleotide, 20 μgo f
nuclear protein extract, and gel shift binding buffer
(Promega) in a final volume of 20 μl. Reaction mixtures
were resolved on 4% nondenaturing polyacrylamide gel
electrophoresis at 200 V for 2 h. Gels were dried and
visualized by autoradiography. Preparation of nuclear
extracts and EMSA was performed a minimum of three
times.
Intracellular Ca
2+ measurements
Cells, grown on 25-mm glass coverslips, were washed
with a physiological medium (KRH) containing NaCl
(125 mM), KCl (5 mM), KH2PO4 (1.2 mM), MgSO4 (1.2
mM), CaCl2 (2 mM), glucose (6 mM), HEPES (25 mM;
pH 7.4), and loaded with 2 μM Fura-2 AM (Molecular
Probes, Inc.) for 50 min at 25°C. The cells were treated
with BBS (10 nM), and single cell changes in the con-
centration of free intracellular Ca
2+ ([Ca
2+]i)w e r e
recorded using a Nikon Diaphot inverted microscope
(Garden City, NY) and a CCD camera (Dage-MTI, Inc.,
Michigan City, IN). Data points were collected every 1-
8S from ~35 cells/coverslip and processed using Image-
Master software. Data are presented as the mean change
in [Ca
2+]i.
Statistical analysis
Statistical analysis was performed using GraphPad InStat
3.0 (GraphPad Software, Inc.). Statistical significance was
assumed if P ≤ 0.05.
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